Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Emergent BioSolutions Inc.
Emergent BioSolutions Reports Financial Results for First Quarter 2009
May 27th, 2009
Emergent BioSolutions Inc. (NYSE:EBS) announced its financial results for the first quarter ended March 31, 2009. Total revenues for the first quarter 2009 increased 51 percent to $64.5 million from $42.7 million in 2008, primarily driven by increased sales of BioThrax® (Anthrax Vaccine Adsorbed), the company’s FDA licensed vaccine for the prevention of anthrax infection. Net income for the first quarter 2009 increased 58 percent to $11.1 million, or $0.37 per share, from $7.0 million, or $0.24 per share, for 2008. R. Don Elsey, chief financial officer of Emergent BioSolutions, stated, “Our first quarter 2009 financial performance reflects the...
Source: Vaccine Weekly (2009-05-27)
|
